LEVOXYL
- Product NDC
- 60793-856
- Requested package NDC
- 60793-856-01
- 11-digit product format
- 607930856
- Labeler code
- 60793
- Product ID
- 60793-856_e230c170-2a16-47d0-bce7-ac0414c192f7
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- levothyroxine sodium
- Dosage form
- TABLET
- Route
- ORAL
- Labeler
- Pfizer Laboratories Div Pfizer Inc
- Application
- NDA021301
- Marketing category
- NDA
- Marketing start
- 2001-05-25
- Substance
- LEVOTHYROXINE SODIUM
- Active strength
- 125 ug/1
- Pharmacologic classes
- Thyroxine [CS], l-Thyroxine [EPC]
- NDC exclude flag
- No
- Listing certified through
- 2026-12-31
- Current FDA listing
- Yes
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N021301-001 | LEVOXYL | LEVOTHYROXINE SODIUM | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 |
| N021301-002 | LEVOXYL | LEVOTHYROXINE SODIUM | 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 |
| N021301-003 | LEVOXYL | LEVOTHYROXINE SODIUM | 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 |
| N021301-004 | LEVOXYL | LEVOTHYROXINE SODIUM | 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 |
| N021301-005 | LEVOXYL | LEVOTHYROXINE SODIUM | 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 |
| N021301-006 | LEVOXYL | LEVOTHYROXINE SODIUM | 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 |
| N021301-007 | LEVOXYL | LEVOTHYROXINE SODIUM | 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 |
| N021301-008 | LEVOXYL | LEVOTHYROXINE SODIUM | 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 |
| N021301-009 | LEVOXYL | LEVOTHYROXINE SODIUM | 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 |
| N021301-010 | LEVOXYL | LEVOTHYROXINE SODIUM | 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 |
| N021301-011 | LEVOXYL | LEVOTHYROXINE SODIUM | 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD, RS | 2001-05-25 |
| N021301-012 | LEVOXYL | LEVOTHYROXINE SODIUM | 0.3MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | RLD | 2001-05-25 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| N021301-001 | AB1 |
| N021301-001 | AB3 |
| N021301-002 | AB1 |
| N021301-002 | AB3 |
| N021301-003 | AB1 |
| N021301-003 | AB3 |
| N021301-004 | AB1 |
| N021301-004 | AB3 |
| N021301-005 | AB1 |
| N021301-005 | AB3 |
| N021301-006 | AB1 |
| N021301-006 | AB3 |
| N021301-007 | AB1 |
| N021301-007 | AB3 |
| N021301-008 | AB1 |
| N021301-008 | AB3 |
| N021301-009 | AB1 |
| N021301-009 | AB3 |
| N021301-010 | AB1 |
| N021301-010 | AB3 |
| N021301-011 | AB1 |
| N021301-011 | AB3 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-02-19 14:30 UTC | 2026-02 | N021301-001 | LEVOXYL | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021301-002 | LEVOXYL | 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021301-003 | LEVOXYL | 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021301-004 | LEVOXYL | 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021301-005 | LEVOXYL | 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021301-006 | LEVOXYL | 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021301-007 | LEVOXYL | 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021301-008 | LEVOXYL | 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021301-009 | LEVOXYL | 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021301-010 | LEVOXYL | 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021301-011 | LEVOXYL | 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD, RS | 2001-05-25 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021301-012 | LEVOXYL | 0.3MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | RLD | 2001-05-25 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021301-001 | LEVOXYL | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021301-002 | LEVOXYL | 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021301-003 | LEVOXYL | 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021301-004 | LEVOXYL | 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021301-005 | LEVOXYL | 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021301-006 | LEVOXYL | 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021301-007 | LEVOXYL | 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021301-008 | LEVOXYL | 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021301-009 | LEVOXYL | 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021301-010 | LEVOXYL | 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021301-011 | LEVOXYL | 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD, RS | 2001-05-25 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021301-012 | LEVOXYL | 0.3MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | RLD | 2001-05-25 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | N021301-001 | LEVOXYL | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | N021301-002 | LEVOXYL | 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | N021301-003 | LEVOXYL | 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | N021301-004 | LEVOXYL | 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | N021301-005 | LEVOXYL | 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | N021301-006 | LEVOXYL | 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | N021301-007 | LEVOXYL | 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | N021301-008 | LEVOXYL | 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | N021301-009 | LEVOXYL | 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | N021301-010 | LEVOXYL | 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | N021301-011 | LEVOXYL | 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD, RS | 2001-05-25 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | N021301-012 | LEVOXYL | 0.3MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | RLD | 2001-05-25 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N021301-001 | LEVOXYL | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | fd3edfee7708… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N021301-002 | LEVOXYL | 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | fd3edfee7708… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N021301-003 | LEVOXYL | 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | fd3edfee7708… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N021301-004 | LEVOXYL | 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | fd3edfee7708… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-02-19 14:30 UTC | 2026-02 | N021301-001 | AB1 | 1 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021301-001 | AB3 | 2 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021301-002 | AB1 | 1 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021301-002 | AB3 | 2 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021301-003 | AB1 | 1 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021301-003 | AB3 | 2 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021301-004 | AB1 | 1 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021301-004 | AB3 | 2 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021301-005 | AB1 | 1 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021301-005 | AB3 | 2 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021301-006 | AB1 | 1 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021301-006 | AB3 | 2 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021301-007 | AB1 | 1 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021301-007 | AB3 | 2 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021301-008 | AB1 | 1 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021301-008 | AB3 | 2 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021301-009 | AB1 | 1 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021301-009 | AB3 | 2 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021301-010 | AB1 | 1 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021301-010 | AB3 | 2 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021301-011 | AB1 | 1 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021301-011 | AB3 | 2 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021301-001 | AB1 | 1 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021301-001 | AB3 | 2 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021301-002 | AB1 | 1 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021301-002 | AB3 | 2 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021301-003 | AB1 | 1 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021301-003 | AB3 | 2 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021301-004 | AB1 | 1 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021301-004 | AB3 | 2 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021301-005 | AB1 | 1 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021301-005 | AB3 | 2 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021301-006 | AB1 | 1 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021301-006 | AB3 | 2 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021301-007 | AB1 | 1 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021301-007 | AB3 | 2 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021301-008 | AB1 | 1 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021301-008 | AB3 | 2 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021301-009 | AB1 | 1 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021301-009 | AB3 | 2 | 31067a03dcf5… |
Observed Orange Book patent history#
| Captured | Edition | Application-product | Patent | Expiration | Use code | Coverage / status | Submission date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-001 | 6555581 | 2022-02-15 | 5c6f7cd8ea54… | |||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-001 | 7067148 | 2022-02-15 | Drug product | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-001 | 7101569 | 2023-10-02 | U-759 | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-002 | 6555581 | 2022-02-15 | 5c6f7cd8ea54… | |||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-002 | 7067148 | 2022-02-15 | Drug product | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-002 | 7101569 | 2023-10-02 | U-759 | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-003 | 6555581 | 2022-02-15 | 5c6f7cd8ea54… | |||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-003 | 7067148 | 2022-02-15 | Drug product | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-003 | 7101569 | 2023-10-02 | U-759 | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-004 | 6555581 | 2022-02-15 | 5c6f7cd8ea54… | |||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-004 | 7067148 | 2022-02-15 | Drug product | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-004 | 7101569 | 2023-10-02 | U-759 | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-005 | 6555581 | 2022-02-15 | 5c6f7cd8ea54… | |||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-005 | 7067148 | 2022-02-15 | Drug product | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-005 | 7101569 | 2023-10-02 | U-759 | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-006 | 6555581 | 2022-02-15 | 5c6f7cd8ea54… | |||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-006 | 7067148 | 2022-02-15 | Drug product | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-006 | 7101569 | 2023-10-02 | U-759 | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-007 | 6555581 | 2022-02-15 | 5c6f7cd8ea54… | |||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-007 | 7067148 | 2022-02-15 | Drug product | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-007 | 7101569 | 2023-10-02 | U-759 | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-008 | 6555581 | 2022-02-15 | 5c6f7cd8ea54… | |||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-008 | 7067148 | 2022-02-15 | Drug product | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-008 | 7101569 | 2023-10-02 | U-759 | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-009 | 6555581 | 2022-02-15 | 5c6f7cd8ea54… | |||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-009 | 7067148 | 2022-02-15 | Drug product | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-009 | 7101569 | 2023-10-02 | U-759 | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-010 | 6555581 | 2022-02-15 | 5c6f7cd8ea54… | |||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-010 | 7067148 | 2022-02-15 | Drug product | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-010 | 7101569 | 2023-10-02 | U-759 | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-011 | 6555581 | 2022-02-15 | 5c6f7cd8ea54… | |||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-011 | 7067148 | 2022-02-15 | Drug product | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-011 | 7101569 | 2023-10-02 | U-759 | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-012 | 6555581 | 2022-02-15 | 5c6f7cd8ea54… | |||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-012 | 7067148 | 2022-02-15 | Drug product | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-012 | 7101569 | 2023-10-02 | U-759 | 5c6f7cd8ea54… | ||
| 2022-04-08 23:34 UTC | 2022-04 | N021301-001 | 6555581 | 2022-02-15 | 5d02ea3f76ae… | |||
| 2022-04-08 23:34 UTC | 2022-04 | N021301-001 | 7067148 | 2022-02-15 | Drug product | 5d02ea3f76ae… | ||
| 2022-04-08 23:34 UTC | 2022-04 | N021301-001 | 7101569 | 2023-10-02 | U-759 | 5d02ea3f76ae… | ||
| 2022-04-08 23:34 UTC | 2022-04 | N021301-002 | 6555581 | 2022-02-15 | 5d02ea3f76ae… |
Additional Listing Data#
- Finished product
- Yes
- Brand name base
- LEVOXYL
- Listing expiration
- 2026-12-31
Active Ingredients#
| Ingredient | Strength |
|---|---|
| LEVOTHYROXINE SODIUM | 125 ug/1 |
Harmonized UNII identifiers#
| Identifier | FDA.report destination |
|---|---|
| 9J765S329G | Internal UNII lookup |
Harmonized RxCUI identifiers#
| Identifier | FDA.report destination |
|---|---|
| 892246 | Internal RxNorm lookup |
| 892251 | Internal RxNorm lookup |
| 966157 | Internal RxNorm lookup |
| 966164 | Internal RxNorm lookup |
| 966170 | Internal RxNorm lookup |
| 966175 | Internal RxNorm lookup |
| 966184 | Internal RxNorm lookup |
| 966190 | Internal RxNorm lookup |
| 966194 | Internal RxNorm lookup |
| 966200 | Internal RxNorm lookup |
| 966204 | Internal RxNorm lookup |
| 966211 | Internal RxNorm lookup |
| 966220 | Internal RxNorm lookup |
| 966221 | Internal RxNorm lookup |
| 966222 | Internal RxNorm lookup |
| 966224 | Internal RxNorm lookup |
| 966225 | Internal RxNorm lookup |
| 966248 | Internal RxNorm lookup |
| 966249 | Internal RxNorm lookup |
| 966253 | Internal RxNorm lookup |
Harmonized SPL set identifiers#
| Identifier | FDA.report destination |
|---|---|
| 758588c3-c63e-491b-0aa2-4f50d80cb174 | Available on FDA.report |
DailyMed Product Concepts#
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 60793-856-01 | LEVOXYL | 100 in 1 BOTTLE | TABLET | 100 | 12 | |
| 60793-856-10 | LEVOXYL | 1000 in 1 BOTTLE | TABLET | 1000 | 12 |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 60793-856-01 | EA - Each | 60793-856 | 5fbd473a-e69a-4354-8cf4-5872a9e0e98f | 1 | 2012-07-24 |
| 60793-856-10 | EA - Each | 60793-856 | 7b7390b8-ebf3-4615-a789-a47260940edb | 1 | 2012-07-24 |
DailyMed Socrata Ingredients#
DailyMed Dashboard NDC Coverage#
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| LEVOXYL | LEVOTHYROXINE SODIUM | Pfizer Laboratories Div Pfizer Inc | 758588c3-c63e-491b-0aa2-4f50d80cb174 | 2020-12-15 | Boxed warning, Warnings, Adverse reactions | 021301 NDA021301 60793-856-01 60793-856 60793085601 |
DailyMed RxNorm Mappings#
Packages#
| Package NDC | 11-digit format | Description | Units | Marketing start | Marketing end | Sample | Exclude flag | Status |
|---|---|---|---|---|---|---|---|---|
| 60793-856-01 | 60793085601 | 100 TABLET in 1 BOTTLE (60793-856-01) | 100 tablet | 2001-05-25 | 0000-00-00 | No | No | Current |